scholarly journals Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

2019 ◽  
Vol 12 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Keren Rouvinov ◽  
Karen Nalbandyan ◽  
Victor Kozlov ◽  
Nir Peled ◽  
Alexander Yakobson
Keyword(s):  
Malignant Melanoma ◽  
Aplastic Anemia ◽  
Metastatic Melanoma ◽  
Active Treatment ◽  
Melanoma Patient ◽  
Case Reports ◽  
Metastatic Malignant Melanoma ◽  
Line Treatment ◽  
Metastatic Melanoma Patient ◽  
Advanced Line

Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient

2021 ◽  
Author(s):  
Alexandra Duplaine ◽  
Camille Prot ◽  
Gwendal Le-Masson ◽  
Antoine Soulages ◽  
Fanny Duval ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Metastatic Melanoma ◽  
Melanoma Patient ◽  
Overlap Syndrome ◽  
Metastatic Melanoma Patient

Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy

2021 ◽  
Vol 31 (3) ◽  
pp. 272-276
Author(s):  
Jens Tijtgat ◽  
Julia Katharina Schwarze ◽  
Gil Awada ◽  
Bart Neyns ◽  
Sandrine Aspeslagh
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Melanoma Patient ◽  
Braf V600e ◽  
Metastatic Melanoma Patient

A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab

2017 ◽  
Vol 27 (2) ◽  
pp. 193-194 ◽  
Author(s):  
Kyosuke Oishi ◽  
Masaharu Nakao ◽  
Shintaro Maeda ◽  
Takashi Matsushita ◽  
Tokuhei Ikeda ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Aseptic Meningitis ◽  
Melanoma Patient ◽  
Metastatic Melanoma Patient

scholarly journals Diffuse Melanosis and Ascites due to Metastatic Malignant Melanoma

2008 ◽  
Vol 8 ◽  
pp. 556-557 ◽  
Author(s):  
Elena Sendagorta ◽  
Angel Pizarro ◽  
Marta Feito ◽  
Matias Mayor ◽  
Paloma Ramírez ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Female Patient ◽  
Metastatic Malignant Melanoma ◽  
Current Evidence ◽  
Rare Entity ◽  
Skin Hyperpigmentation

We present a female patient who developed mucosal and skin hyperpigmentation due to metastatic malignant melanoma. Diffuse cutaneus melanosis is a rare entity that complicates a small percentage of metastatic melanomas, confering a fatal prognosis. We discuss briefly the current evidence on pathogenesis of melanosis arising from metastatic melanoma.

scholarly journals Cytokine-Enhanced Vaccine and Suicide Non-Viral Gene Therapy in Advanced Metastatic Melanoma Patients: Two Case Reports

2020 ◽  
pp. 1-4
Author(s):  
Gerardo C. Glikin ◽  
Gerardo C. Glikin ◽  
Heliana L. Hernández-Herrera ◽  
Liliana M. E. Finocchiaro ◽  
Ventura A. Simonovich
Keyword(s):  
Gene Therapy ◽  
Metastatic Melanoma ◽  
Primary Tumor ◽  
Melanoma Patient ◽  
Case Reports ◽  
Suicide Gene ◽  
Viral Gene ◽  
Immune Gene ◽  
Slowing Down ◽  
Inguinal Lymphadenectomy

The prognostic for metastatic melanoma is very poor when treated with standard cytotoxic chemotherapies and it is often refractory to check point inhibitors and/or molecular targets. In this context the development of new treatments with better efficacy and safety profiles is highly desirable. Based on our successful experience applying suicide and immune gene therapy in a veterinary clinical setting, we are proposing its translation to human patients. We are presenting here the first-in-human safety assay of this approach. We report two cases of refractory metastatic melanoma. The first-one was a 27-years-old pharyngeal mucosal melanoma patient with a primary tumor in his left tonsil. Despite transient slowing down, the disease successively progressed to radiotherapy, radical surgery, ipilimumab, nivolumab, imatinib and temozolomide. The second-one was a 72-years-old malignant melanoma patient with a primary tumor in his left hallux. Despite transient slowing down, the disease successively progressed to hallux amputation, inguinal lymphadenectomy, radiotherapy, interferon-alpha, ipilimumab, pembrolizumab and temozolomide. The proposed treatment included local intratumoral suicide gene therapy concomitant with a subcutaneous vaccine composed by allogeneic tumor extracts and liposomes with plasmids bearing IL-2 and GM-CSF genes. The treatment was safe: the only side effects were from mild to moderate and manageable: pyrexia, swelling of the injected tumor and partial hair loss (alopecia). Due to disease progression both patients were withdrawn from the study before completing the complete series of interventions. These preliminary data encourage the completion of further clinical trials to establish the possible clinical benefit of the proposed approach.

scholarly journals Case Report: Treatment Resistant Ipilimumab Related Colitis in an Elderly Metastatic Melanoma Patient

2018 ◽  
Vol 07 (01) ◽  
Author(s):  
Nicolas Marechal ◽  
Sofie Wilgenhof ◽  
Bart Neyns ◽  
Veerle Morlion ◽  
Daniel Urbain ◽  
...  
Keyword(s):  
Case Report ◽  
Metastatic Melanoma ◽  
Melanoma Patient ◽  
Treatment Resistant ◽  
Metastatic Melanoma Patient

New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient

2015 ◽  
Vol 50 (1) ◽  
pp. e2-e4 ◽  
Author(s):  
Elisabetta Miserocchi ◽  
Carolina Cimminiello ◽  
Marco Mazzola ◽  
Vincenzo Russo ◽  
Giulio M. Modorati
Keyword(s):  
Metastatic Melanoma ◽  
Melanoma Patient ◽  
Metastatic Melanoma Patient ◽  
New Onset
Sign in / Sign up

Export Citation Format

Share Document